Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
PFE Pfizer Inc
AGNC Agnc Investment Corp
AAPL Apple Inc
GRTYA Guaranty Corp
SATS EchoStar Corp
$DJI Dow Jones Industrials
TIKK Tel-Instrument Electronics Corp
TEAM Atlassian Corporation PLC
PAYX Paychex Inc
Go

Health Care : Pharmaceuticals | Large Cap Blend
Based in Switzerland
Company profile

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$91.44
Day's Change
1.20 (1.33%)
Bid
--
Ask
--
B/A Size
--
Day's High
91.52
Day's Low
91.01
Volume
(Light)

Today's volume of 642,077 shares is on pace to be much lighter than NVS's 10-day average volume of 2,601,086 shares.

642,077

Molecular Diagnostics Market Rises at 7.1% CAGR and Hit US$ 13,873.6 Mn by 2025; Clinical and Pathology Labs to Show Higher Demand, says Fortune Business Insights

8:14 am ET October 27, 2020 (Globe Newswire) Print

The rising incidence of infectious diseases is fueling demand in the global molecular diagnostics market. Fortune Business Insights (FBI) has published a report, titled "Molecular Diagnostics Market Size, Share and Global Trend by Product Type (Instruments Reagents & Consumables), Application (Infectious Disease, Blood Screening, Histology & Oncology), Technique (Hospitals Amplification, Hybridization & Sequencing Techniques), End User (Hospitals, Clinical & Pathology Labs) and Geography Forecast till 2025".

According to the report, the global molecular diagnostics market is expected to reach a value of US$ 13,873.6 Mn by 2025 from US$ 8,012.7 Mn in 2017. The market is expected to rise at a CAGR of 7.1%, driven by rising microbial outbreaks.

Molecular Diagnostic Industry Developments:

-- In May 2019, Qiagen, a Germany based company got FDA approval for its QIAstat-Dx syndromic testing system. The newly FDA approved system is equipped with an advanced DiagCORE technology which enables effective detection of around 20 types of pathogens.

-- In April 2018, altona Diagnostics GmbH launched an advanced marked AltoStar Molecular Diagnostic Workflow with an aim to streamline the workflow in real-time PCR infectious disease testing.

-- In July 2015, Rosetta Genomics Ltd. launched OncoGxSelect, a next generation sequencing oncology panel. The new system enables detection of 5 types of genes which are associated with the lung cancer.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/molecular-diagnostics-market-100086

Lucrative Reimbursement Policies to Support Growth Pathology Labs and Hospitals Segment

Among techniques available in the market, the report predicts the demand for sequencing techniques to rise at a higher rate. The demand for amplification techniques is also expected to rise during the forecast period. This is because amplification techniques are used for the detection of micro-organisms, quantification and genotyping and their demand is more as compared to the other segments

Among products available in the molecular diagnostic market, the report predicts the demand for reagent and consumables to rise at a higher rate. Similarly, on the basis of end user, the clinical and pathology labs and hospitals segments are expected to show higher demand for molecular diagnostics. Growth in these segments is attributable to lucrative reimbursement policies offered by governments around the world.

To get to know more about the short-term & long-term impact of COVID-19 on this market, please click here: https://www.fortunebusinessinsights.com/industry-reports/molecular-diagnostics-market-100086

Increasing Incidence of Hospital-Acquired Infections to Fuel Demand for Molecular Diagnostics

According to 2019 report by World Health Organization, the average rate of infections acquired from hospitals in Europe is 7.1% and that in the U.S. is 4.5% respectively. This is indicative of the increasing incidence of hospital acquired infections. This, coupled with rising prevalence of infectious diseases, is boosting the market for molecular diagnostics.

Besides this, advanced molecular diagnostic techniques facilitate the diagnosis of infectious diseases as they provide accurate and prompt results. This factor will further drive the market in the long run.

On the flipside, stringent rules of approval for molecular diagnostic processes may hamper the market to an extent. Manufacturers often face uncertainties regarding the commercialization of their products because of the strict rules imposed by governments, which may adversely impact the global molecular diagnostics markets.

Furthermore, the absence of a strong framework for genomic and personalized medicine in mature markets such as in the U.S. is anticipated to create hindrances for the market. Despite a large population, the lack of well-defined regulatory guidelines and framework in the diagnostic sector may hamper the growth of the market for molecular diagnostics in emerging nations such as China and India.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/molecular-diagnostics-market-100086

Huge Investments by Major Players to Propel Growth

Increasing government funding for clinical studies in molecular diagnostics will propel growth in the molecular diagnostics market. This is aimed at curbing the incidence of microbial outbreaks. For instance, recent bacterial and viral outbreaks in the Middle East and Africa compelled several research institutions and governments organizations to conduct researches on molecular diagnostics. Such initiatives will also pave way for the advent of novel therapeutics in molecular diagnostics.

For example, organizations such as Oracle Partners, Oracle Institutional Partners, and Schuler Family Foundation invested about US$ 19.5 million in diagnostics for developing and distributing infectious disease IVD tools and tests. Such investments will bode well for the molecular diagnostics market in the long run.

List of the companies operating in the global molecular diagnostics market are:

-- bioMerieux SA.

-- BD

-- Danaher

-- Grifols, S.A.

-- Hologic Inc.

-- Novartis AG

-- QIAGEN

-- Siemens Healthcare GmbH

-- F. Hoffmann-La Roche Ltd.

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/molecular-diagnostics-market-100086

Molecular Diagnostics Market Segmentations:

By Product Type

? Instruments

? Reagents & Consumables

By Application

? Infectious Disease

? Blood Screening

? Histology

? Oncology

? Others

By Technique

? Amplification Techniques

? Hybridization Techniques

? Sequencing Techniques

? Others

By End User

? Hospitals

? Clinical & Pathology Labs

? Others

By Geography

? North America (USA and Canada)

? Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

? Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

? Latin America (Brazil, Mexico and Rest of Latin America)

? Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Inquire Before Buying: https://www.fortunebusinessinsights.com/enquiry/queries/molecular-diagnostics-market-100086

SECONDARY DATA SOURCES THAT WE REFER TO:

-- Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market

-- Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.

-- Website, reports, and press releases of end user facilities - Hospitals, Ambulatory Surgery Centres, Clinics

-- Industry journals and paid databases

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

-- Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies

-- Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.

-- Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility

-- Number of procedures and average price of procedures

-- Replacement rate and pricing of capital equipment

-- Market dynamics in relation to the market under focus - Drivers, restraints, trends, and opportunities

-- Market & technological trends, new product developments, product pipeline.

Have a Look at Related Reports:

Point of Care (POC) Diagnostics Market Share and Global Trend By Product (Blood Glucose Monitoring, Infectious Diseases, Cardiometabolic Diseases, Pregnancy and Fertility Testing Products, Hematology Testing Products, Others), By End User (Hospitals Bedside, Physician's Office Lab, Urgent Care & Retail Clinics, Home and Self Testing) and Geography Forecast till 2026

Psoriatic Arthritis Treatment Market Share and Global Trend By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies) and Geography Forecast till 2026

In-vitro Diagnostics (IVD) Market Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019 - 2026

Immunodiagnostics Market Share and Global Trend By Product Instruments, Reagents & Consumables), By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases), By End user (Clinical Laboratories, Hospitals, Physician's Offices), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Geography Forecast till 2026

Antithrombin Market Share and Global Trend By Application (Therapeutics, Research, Diagnostics & Others), Source (Human, Goat Milk), Dosage Form (Lyophilized, Liquid) & Geography Forecast till 2025

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights(TM) Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Fortune Business Insights(TM)

LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/molecular-diagnostics-market-9028

https://ml.globenewswire.com/media/05408ba1-26b1-4fdd-8f48-1af4df373348/small/fbi-logo-tm-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.